PLGA Microsphere Formulation Development — Case Study Redesign :root{ –ink:#101d2b; –paper:#f6f5f1; –panel:#ffffff; –teal:#1b6e71; –teal-dim:#e4eeed; –amber:#b8802e; –amber-dim:#f4e9da; –slate:#57626e; –line:#e1ddd2; –line-dark:#28394a; } […]
Case Study: PLGA Microsphere Formulation Development for a 3-Month Depot Antipsychotic Read More »
Introduction: Bioequivalence study bioanalytical services are the laboratory backbone of every generic drug approval, formulation change, and lifecycle management submission
Introduction: Nitrosamine leachables in blister packaging have become one of the most closely scrutinized contamination pathways in oral solid dosage
Introduction: Trastuzumab biosimilar analytical characterization is the foundation on which any HER2-targeted biosimilar’s regulatory approval is built, since agencies require
Introduction: Peptide therapeutics are one of the fastest-growing drug classes in the pharmaceutical pipeline, but their structural complexity demands rigorous
Introduction: PLGA for pulmonary drug delivery has become a focal point for formulators seeking to extend the therapeutic window of
Introduction: Dexamethasone Injection Development has become increasingly sophisticated as pharmaceutical companies pursue preservative-free injectable products designed to meet evolving clinical
Preservative-Free Dexamethasone Injection Development Read More »
Introduction: The role of PK/PD studies in biosimilar development has become one of the most closely watched questions in biologics
Introduction: Nitrosamine testing for proton pump inhibitors has become a non-negotiable part of regulatory compliance for manufacturers of omeprazole, esomeprazole,
Introduction: The immunogenicity of peptide-oligonucleotide conjugates is one of the most consequential development risks facing sponsors working with this rapidly
